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Abstract 
 
     The overgrowth and disequilibrium of pathogenic microorganism species both native 
and non-native to the oral cavity can manifest into a variety of different oral diseases, 
pathologies, and afflictions in humans, including dental caries, gingivitis, pharyngitis, 
halitosis, and oral candidiasis. Two bacterial strains with clinically-significant probiotic 
applications in curtailing the pathogenic bacterial growth involved in these conditions are 
Streptococcus salivarius strain K12 and Streptococcus salivarius strain M18. To 
summarize the most up-to-date in vitro, in vivo, and clinical research findings, 
administration of these S. salivarius strains typically in the form of probiotic lozenges 
results in colonization, reduction in inflammatory measures, and marked alterations to 
physical structure & gene expression of the oral epithelial cells of the pharynx, tongue, 
and buccal membrane. While K12 and M18’s reduction of pharyngitis and halitosis has 
been largely attributed to bacteriocin production, the probiotic strains utilize different 
modes of action to reduce other oral pathologies. The prevention of dental caries, 
gingivitis and oral candidiasis appears to be ultimately influenced by K12 and M18’s 
production of dextranase & urease, reduction of inflammatory cytokines, and direct 
physical attachment to pathogens, respectively. In addition to conferring several oral 
health benefits, these S. salivarius strains have been proven extremely safe for human 
consumption in clinical trials and have the potential for universal application as an 
alternative treatment to antibiotics in the aforesaid oral pathologies. 
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Introduction 
 
     The well-defined interconnectivity between oral cavity health and systemic bodily 
health has earned the mouth the rightly-deserved title “the gateway to the body”. Oral 
health plays a variety of roles in maintaining overall systemic health and therefore, good 
oral health is essential for the well-being of humans. A significant contributor to oral 
health status is the vast microbiome of bacteria, fungi, and other organisms that reside 
within the oral cavity. At a given point in time, approximately 700 different taxa of 
bacterial species simultaneously inhabit the human mouth.1 Some of these taxa are 
“good” bacteria that are capable of providing benefits to the oral cavity (and to the body 
as a whole), and some of these “bad” bacterial taxa exert detrimental effects. The “bad” 
bacteria can be problematic to humans by engendering dental caries, periodontal disease, 
strep throat, and a wide range of other diseases. The “good” bacteria have a host of 
beneficial effects on humans, including immunomodulation and prevention of pathogen 
colonization.1 Certain “good” microorganisms can dampen the effects of “bad” microbes, 
while providing a host of positive effects on the oral cavity and body as a whole. 
     As a result of the beneficial qualities of certain “good” bacterial species, 
microbiologists conceived the notion of utilizing supplements of these species for human 
consumption. A discrete dose of viable “good” bacteria which confers benefits to the 
individual receiving the supplement is referred as a probiotic. One particularly important 
benefit of probiotics is the ability to treat inflammatory diseases and infections. Different 
probiotics can exert beneficial effects in specific targeted areas along the digestive tract, 
beginning at the oral cavity and ending at the colon. The majority of primary research 
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focuses on the gastrointestinal benefits of probiotics, but probiotics can indeed exert a 
wide array of benefits on other parts of the body, such as the oral cavity.2 Compared to 
their gastrointestinal probiotic counterparts, these “oral probiotics” are relatively new 
probiotic formulations capable of combatting “bad” bacteria and disease in the oral 
region, which is extremely fundamental from a health perspective.  
     Of particular importance and the subject of extensive research, one “good” bacterial 
species that is utilized as a commercial oral probiotic is Streptococcus salivarius. This 
species is a spherical, gram positive, oxidase negative, and catalase negative bacterium.3 
S. salivarius is one of the earliest colonizers of the epithelial lining of the human mouth 
and nasopharynx.1 The bacterium colonizes the tongue dorsum and pharyngeal mucosa of 
infants, who acquire the bacterium from their mother within two days after birth.4 The 
two most well-studied strains of S. salivarius that are currently employed as probiotics 
are strains K12 and M18. S. salivarius K12 was first isolated from the saliva of a healthy 
child, and has been utilized as a commercial probiotic in New Zealand for over a decade.5 
K12 produces salivaricin A2 and salivaricin B, two bacteriocins that effectively inhibit 
phylogenetically related bacterial species.6 In the human population, approximately 2% of 
children naturally possess S. salivarius strains that produce both salivaricin A and 
salivaricin B, which corresponds to the strain K12 bacteriocin profile.6 Due to K12’s 
bacteriocin profile that effectively inhibited strep-throat-causing bacterial species in 
preliminary studies, BLIS K12 was commercially developed and thus became the first 
S. salivarius K12 oral probiotic to specifically target oral health. Another well-studied 
strain of S. salivarius is strain M18. This strain exhibits a markedly different bacteriocin 
profile compared to strain K12 and effectively secretes the bacteriocins A2, 9, MPS and 
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M.7 Due to M18’s ability to inhibit dental caries-causing pathogens, BLIS M18, which 
utilizes active strains of S. salivarius M18, was commercially developed to focus on 
dental health issues that K12 seemingly cannot address.7  
     When K12 and M18 are first introduced into the oral cavity typically in the form of a 
probiotic lozenge, they must colonize specific oral regions and be tolerated by the human 
host. Once the bacteria establish themselves, they can then confer their individually 
distinct oral health benefits to the human host. This primary research literature review 
will synthesize and analyze the most current research on these two commercially-utilized 
probiotic strains by discussing the colonization pattern and commensal relationship of 
K12 and oral epithelial cells, the clinical benefits that each strain confers to humans and 
the proposed mechanisms, oral probiotic safety and future implications. 
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Colonization of the Oral Cavity by S. salivarius K12 & M18 
      
     Before S. salivarius K12 and M18 can exert their beneficial oral health effects, they 
must first effectively colonize the oral cavity. To begin their colonization of the oral 
cavity, individual S. salivarius K12 cells must adhere to oral epithelial cells and then 
rapidly reproduce to form colonies. Orf166, an open reading frame that is present on 
K12’s megaplasmid, encodes a cell-surface protein, which ultimately enables this strain 
to attach to HEp-2 epithelial cells, along with the help of other adhesion factors.8 Once S. 
salivarius K12 attaches, there is a remodeling of the host epithelial lining to facilitate the 
commensal interaction between the bacterial and host cell.1 Specific epithelial cell 
cytoskeleton-related and adhesion-related genes are upregulated and downregulated, 
suggesting structural and adhesive changes in epithelial cells that can strengthen the cells’ 
interactions with K12.1 Once BLIS K12 has adhered to the epithelial lining, it colonizes 
areas along the upper respiratory tracts of children, including the oral cavity, 
nasopharynx, and adenoid tissues.9 Within the oral cavity itself, the colonization sites of 
S. salivarius K12 are primarily the pharynx, tongue, and buccal membrane.4 K12 
colonizes the pharynx to a greater degree than the tongue and buccal membrane, 
reproducing to approximately 1.24x105 CFU compared to 1.3x104 CFU and 4.6x104 
CFU, respectively.4 Even so, the colonies make up only less than 1% of the entire 
population of bacterial flora in these particular regions.4 Following human consumption 
of K12 lozenges, the strain can last in these areas for as long as three weeks, but the 
CFUs tend to decrease dramatically after a week.4 In the saliva, S. salivarius can be 
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present in concentrations as high as 1x107 CFU/mL, which greatly surpasses the colonial 
concentrations in the other oral regions.7  
     Similar to the patterns of colonization by K12, the colonization of the oral cavity by S. 
salivarius M18 is dose-dependent.8 When larger dosages are administered, an increased 
number of M18 bacteria are retained over a period of time.8 However, when a persistent 
lower dosage is administered, there is no cumulative increase in the concentration of M18 
in the oral cavity.8 Upon M18 colonization of the oral cavity, there is little to no 
widespread perturbation of the oral microbiome.8 Instead of large-scale shifts in bacterial 
composition, the proportions of bacterial species only shift slightly.8 This experimental 
data supports the clinical safety of the strain, as extensive disturbances in the microbiota 
of healthy subjects are not desirable; significant alterations could potentially yield 
negative impacts on the probiotic consumers. 
     Research shows that the form of probiotic bacteria that is consumed does indeed have 
an effect on rates of oral bacterial colonization. For example, BLIS K12 Throat Guard, 
a lozenge containing strain K12, demonstrates an 80% effectiveness in colonizing the 
oral cavity of those who consume the probiotic.10 However, when the consumers ingest 
the non-lozenge powdered formula of the probiotic, the effectiveness greatly diminishes 
to 33%.10 The reduced efficacy of the powdered form can be attributed to a reduced oral 
cavity exposure time compared to when the lozenge form is administered.10 Therefore, 
the apparent method for an efficacious administration of S. salivarius K12 appears to be 
the probiotic lozenge form, as opposed to the powdered variation. 
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The Commensal Relationship of S. salivarius K12 & Oral 
Epithelial Cells 
      
     Once the strains of S. salivarius have colonized the oral cavity, the oral epithelial cell 
structure and gene regulation are influenced by strain K12 to facilitate a commensal 
relationship. S. salivarius K12’s probiotic quality can be attributed to its unique 
interactions with oral epithelial cells that modulate physiological responses and innate 
defenses. Through its interactions with the host cells, S. salivarius promotes oral health, 
maintains homeostasis by reducing inflammation and pathogen-induced apoptosis, and 
allows itself to be tolerated by the human host.1 S. salivarius K12 accomplishes these 
actions by inhibiting a pro-inflammatory response, stimulating an anti-inflammatory 
response, and modulating genes related to adhesion & homeostasis.1  
     S. salivarius K12 downregulates the inflammatory response by inhibiting the NF-B 
pathway in human bronchial epithelial cells (16HBE14O-).1 K12 does not initiate the 
synthesis of pro-inflammatory cytokines or chemokines. In fact, the strain actually 
decreases normal interleukin-8 (IL-8) secretion, as well as its secretion when epithelial 
cells are exposed to pathogenic Pseudomonas aeruginosa, Salmonella serovar 
Typhimurium flagellin, and the immunomodulatory host defense peptide LL-27.1 
Growth-related oncogene alpha (Gro), which is involved in leukocyte recruitment and 
proliferation, was similarly downregulated when exposed to flagellin in the presence of 
K12 cells.1 Taken together, the downregulation of these processes illustrates the K12-
induced reduction of the inflammatory response 
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     In addition to inhibiting a pro-inflammatory response, K12 also stimulates an anti-
inflammatory response. When human bronchial epithelial cells are exposed to S. 
salivarius K12 and gene expression in these epithelial cells is analyzed, NF-B-
stimulated binding sites in the promoter regions of K12-modulated genes are 
underrepresented.1 This underrepresentation ultimately leads to a response that is anti-
inflammatory. In addition, the nicotinic acetylcholine pathway was overrepresented.1 
This pathway has the potential for anti-inflammatory effects through its suppression of 
IB phosphorylation and NF-B-induced transcription.1 Furthermore, the binding sites 
for CREB, a transcription factor that has been implicated in anti-inflammation, were 
significantly overrepresented in cells treated with K12.1 Additional expression data 
demonstrates an underexpression of proapoptotic FAS signaling and transforming growth 
factor  pathways, both of which have anti-inflammatory consequences.1 
     Finally, K12 modulates homeostatic genes involved in transcription, translation, 
protein trafficking, exocytosis, nucleoside metabolism, and phosphate metabolism.1 As 
previously discussed, the expression of genes involved with the cytoskeleton and 
adhesion are also modulated by strain K12. Based on the collective experimental data, the 
gene expression patterns suggest an attenuated epithelial cell inflammatory response in 
response to S. salivarius. In conclusion, K12 modulates genes involved in the innate 
response pathways and epithelial cell homeostasis to ensure that it is tolerated by the 
human host.  
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Oral Health Benefits of S. salivarius K12 & M18 Probiotics 
      
      After becoming established in the oral cavity, S. salivarius K12 and M18 can exert 
their beneficial probiotic health effects on the human host. Both the K12 and M18 strains 
have demonstrated the potential to provide a wide array of health benefits to human hosts 
based on in vitro, in vivo, and clinical experimental investigations. One particularly 
significant benefit is the reduction of oral diseases, maladies, and afflictions including: 
(1) pharyngotonsillitis, pharyngitis & tonsillitis, (2) dental caries, (3) gingivitis & 
periodontitis, (4) halitosis, and (5) oral candidiasis.  
(1) Pharyngotonsillitis, Pharyngitis & Tonsillitis 
     Pharyngitis and tonsillitis both involve the symptoms of redness, pain, and 
inflammation of the throat and tonsils, respectively. Group A beta-hemolytic 
streptococci are typically the culprit of bacterial-induced pharynigitis.2 The 
bacterium responsible for the large majority of bacterial pharyngitis cases is 
Streptococcus pyogenes, and if untreated, infection can result in rheumatic fever, 
deep space abscesses, and toxic shock.9 Some cases of pharyngitis can become 
chronic, with recurrent episodes of infection.9 When patients diagnosed with 
recurrent pharyngitis consume Bactoblis, which contains S. salivarius K12, they 
exhibit an 80-96% reduction in the number of episodes of streptococcal 
pharyngitis and/or tonsillitis infections during a 90-day treatment regimen.2, 9, 11 
Following the 90 day regimen, they similarly exhibit a 60% reduction in the 
number of reports of pharyngitis in the six month period following the Bactoblis 
regimen.9 Retrospective studies of children with recurrent pharyngitis who were 
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treated with S. salivarius K12 Bactoblis demonstrate the same trend of a 
significant reduction in pharyngitis cases throughout the course of treatment and 
for the following 9 months post-treatment.12 In addition to preventing -hemolytic 
streptococcal pharyngeal infections, one study reports an 80% reduction in viral 
pharyngeal infections.11 This result should be further investigated to explore the 
potential for K12 in reducing non-bacterial infections.  
     The prevention of S. pyogenes infections can be attributed to the production of 
lantibiotics, a specific classification of antimicrobial peptides that contain 
lanthionine.13 These lantibiotics are a subgroup of bacteriocins, which interfere 
with the growth of bacteria that are phylogenetically-similar to S. salivarius.12 
Strain K12 is capable of producing two lantibiotics: salivaricin A2 (SalA2) and 
salivaricin B (SboB).14 Although salivaricin A2 and salivaricin B are 
simultaneously produced in this particular strain of S. salivarius, they are 
unrelated peptides.14 SalA2 is a 2,368-Da peptide that has two amino acid 
substitutions at position 4 (S  T) and at position 7 (I  F) that differentiate this 
variant from salivaricin A.14 SboB, a 2,740-Da peptide, is encoded by a cluster of 
eight genes that is flanked by large inverted repeat sequences.13 Salivaricin B’s 
mode of action in reducing S. pyogenes is bactericidal.15 It is a broad-spectrum 
lantibiotic, capable of inhibiting the growth of Streptococcus sanguinis, 
Streptococcus equisimilis, Streptococcus agalactiae, Streptococcus pneumoniae, 
Streptococcus sobrinus, Corynebacterium dyptheriae, Lactobacillus casei, 
Stomatococcus mucilagenosus, and Moraxella catarrhalis.15 The loci of the genes 
that encode salivaricin A2 and salivaricin B are located nearly adjacent to one 
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another on a 190-kb megaplasmid- the separation is only about 7.5-kb.13 K12 can 
transfer its megaplasmid to different S. salivarius strains in subjects who are K12-
colonized, indicating that the genes encoding salivaricin A2 and B are indeed 
transmissible.15 When the megaplasmid is removed from a K12 bacterium, there is 
no longer an antagonistic influence on the growth of S. pyogenes.2 Altogether, the 
data demonstrates that S. salivarius strain K12’s secreted lantibiotics are capable 
of inhibiting this prominent pharyngitis-causing bacterial species.2  
     While K12 produces A2 and B, S. salivarius strain M18 produces salivaricin 
A2, 9, MPS, and M.7 Salivaricin A2, MPS, and 9 are all megaplasmid-encoded 
and capable of inhibiting S. pyogenes.7 While MPS, a 60-kDa peptide, has an 
inhibitory effect specific to S. pyogenes, A2 and 9 are both broader in their 
actions, capable of inhibiting additional respiratory tract pathogens.7 Salivaricin 
M is responsible for inhibiting mutans streptococci and its expression is 
chromosomally-regulated.7 
     S. salivarius K12 was the first bacterium known to produce two distinct 
lantibiotics.13 As production of these lantibiotics is energetically costly, producing 
multiple bacteriocins indicates the important role of S. salivarius in maintaining 
microbiological balance in the oral cavity.13 The K12 bacteriocins have strong in 
vitro inhibitory activity against S. pyogenes, which provides a means of reducing 
the presence of this pharyngitis and tonsillitis-causing microbe in the oral cavity.7 
In addition to the bacteriocin-based mode of inhibition, K12 cells bind strongly to 
human epithelial cells (HEp-2 cells) and competitively interfere with S. 
pyogenes’s binding to this same cell line.7 
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(2) Dental Caries 
     Dental caries is one of the most common childhood diseases and is 
characterized by the breakdown of tooth enamel and dentin due to “bad” 
bacteria.16 These “bad” bacteria release organic acids that reduce the pH of the 
oral cavity. The lowered environmental pH causes the dissolution of 
hydroxyapatite matrices of enamel and dentin.17 Typically, a combination of 
mutans streptococci (particularly Streptococcus mutans and Streptococcus 
sobrinus) and individual factors (i.e. saliva composition, fluoride exposure, 
dietary & hygiene habits, etc.), can stimulate this decrease in the pH of the oral 
cavity.16  
     Treatment with S. salivarius M18 effectively reduces a patient’s risk of 
developing dental caries through a molecular mechanism that increases oral pH 
and reduces plaque formation. In one study, the risk of a patient developing dental 
caries is assessed through Cariogram, a software program that identifies the 
relative risk of developing caries based on nine pathological and protective 
factors, coupled with the expertise of the dentist.16 When children who are at 
“high risk” for developing caries are treated with Carioblis, an oral probiotic 
containing S. salivarius M18, they are less likely to develop dental caries based 
on the Cariogram outcome following a 90-day regimen.16 In the untreated control 
group, on average, there was a 20% chance of avoiding cavities at day zero and 
this percentage only slightly increased to 37% after a period of 90 days.16 In the 
M18-treated group, at day zero, subjects had an average of a 20% chance of 
avoiding new cavities (which mirrors that of the control group), while this 
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percentage significantly increased to 70% after the 90 day treatment.16 Not only 
was the overall chance of developing dental caries significantly reduced by the 
M18 treatment regimen, but the amount of plaque and mutans streptococci both 
decreased by approximately 50% and 75%, respectively.16 The untreated control 
group did not exhibit any differences in concentration of plaque or mutans 
streptococci.  
     The treatment of dental caries using S. salivarius M18 probiotics appears to 
yield greater benefit and effectiveness in a certain group of patients. Participants 
who have high plaque scores receive a greater degree of benefit from M18 
treatment, as they exhibit superior levels of plaque reduction.18 Additionally, 
patients who are colonized by S. salivarius M18 demonstrate greater plaque 
reduction compared to those subjects who were not colonized and were merely 
exposed to the bacterial probiotics.18 Similarly, those patients who are M18-
colonized exhibit a greater reduction of S. mutans.18 Studies indicate that higher 
levels of colonization result in a greater reduction of this caries-causing bacterium 
in saliva, and thus an overall reduction in the development of dental caries itself.18  
     This significantly decreased risk of developing dental caries due to a 90-day S. 
salivarius M18 regimen can be attributed to several proteins produced by the 
strain. As previously discussed, M18 releases salivaricin M, which limits the 
growth of the caries-causing bacterial species, S. mutans and S. sobrinus.16 
Moreover, the strain secretes dextranase and urease. While dextranase catalyzes 
the breakdown of dextran, urease facilitates the hydrolysis of urea.16 As dental 
plaques are rich in dextran, dextranase can aid in solubilizing the plaques that 
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contribute to the breakdown of tooth enamel and dentin. Similarly, urease can 
increase the pH of saliva by breaking down urea into carbon dioxide and 
ammonia, and thus prevent hydroxyapatite dissolution. Therefore, dextranase and 
urease are two M18 enzymes that are effective in decreasing rates of dental caries 
by reducing plaque accumulation and plaque acidification, respectively.16  
(3) Gingivitis & Periodontitis 
     Gingivitis is characterized by the inflammation of the gingiva as a result of 
excess plaque, while periodontitis is a more severe form of gum disease that 
involves the gingiva pulling away from the teeth. Periodontal disease can be 
caused by several bacterial species, including Porphyromonas gingivalis, 
Aggregatibacter actinomycetemcomitans, and Fusobacterium nucleatum.3 These 
bacteria implicated in gingivitis and periodontitis induce inflammation of the 
gums by releasing multiple cytokines, including IL-6 and IL-8 .3 Another 
contribution to the development of gingivitis and periodontitis is the accumulation 
of plaque on the surfaces of human dentition, especially near the gingiva.18  
     When BLIS M18 lozenges are administered to subjects, measures of gingivitis 
including supragingival plaque, gingival inflammation, sulcular bleeding, and 
probing pocket depth using a Williams periodontal probe are all significantly 
reduced compared to baseline levels prior to consuming the probiotic.19 After a 
cease in the regimen, there is an increase in all these parameters, such as an 
increased number of bleeding sites.19 Both strains K12 and M18 are capable of 
reducing P. gingivalis, A. actinomycetemcomitans, and F. nucleatum-induced IL-
6 and IL-8 levels, which are important indicators of the level of inflammation in 
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periodontal disease.3 The previously described ability of K12 to reduce the 
production of cytokines when it is commensally associated with oral epithelial 
cells, coupled with its ability to reduce cytokine levels induced by gingivitis-
causing bacterial species, further supports K12’s anti-inflammatory role in the 
oral cavity. Moreover, as S. salivarius M18 confers plaque reduction to human 
hosts, this can be an additional means of reducing the gingival inflammation 
involved in gingivitis.18 In summary, the probiotics M18 and K12 reduce levels of 
gingival inflammation and plaque, which in turn leads to a reduction in severity 
measures of gingivitis and periodontitis.  
(4) Halitosis 
     Although halitosis, commonly known as oral malodor or “bad breath”, is not a 
medical problem, it is a generally undesirable oral hygiene concern.20 Halitosis is 
prominently treated by using antimicrobial agents or mechanical devices to reduce 
bacterial populations that particularly inhabit the lingual region of the oral 
cavity.21 Halitosis is primarily caused by the presence of volatile sulfur 
compounds (VSC), sulfur-containing metabolic by-products of anaerobic 
bacteria.20 S. salivarius itself does not produce large quantities of VSCs, and 
therefore has an extremely minimal contribution to oral malodor.20 When 
lozenges containing S. salivarius K12 are consumed for a week by human 
subjects with high VSC levels, their VSC levels were significantly reduced in 
85% of test subjects, indicating a reduction in this important marker of halitosis.20 
Moreover, there was the greatest bacterial composition change in the group that 
received S. salivarius lozenges, and K12 was detected in the saliva samples of 
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subjects after 7 and 14 days.20 The subjects that had larger quantities of K12 
present in saliva samples exhibited the greatest reduction in VSC levels.  
     Even if the host is not colonized by K12, the bacteria are still capable of 
increasing the lantibiotic concentrations in saliva, which can be effective in 
reducing halitosis-causing bacterial species. In vitro, K12 reduces the growth of 
black-pigmented bacteria and several Gram-positive bacterial species implicated 
in halitosis by producing salivaricin A and salivaricin B.20 The Gram-positive 
bacteria that are implicated in halitosis that S. salivarius inhibits include: 
Streptococcus anginosis T29, Eubacterium saburreum, Micromonas micros, 
Atopobium parvulum, Eubacterium sulci, Parvimonas micra, and Solobacterium 
moorei.22 Although K12 antagonizes numerous Gram-positive bacteria that cause 
halitosis, there are no known Gram-negative bacteria that are effectively 
inhibited.22 When halitosis-causing bacterial species are reduced and replaced 
with non-halitosis-causing bacterial species (such as S. salivarius K12), this 
serves as a viable means to reduce halitosis. 
     As current treatments for halitosis tend to have short-term results, with VSC-
producing bacteria quickly repopulating the oral cavity, there is a present need for 
a longer-term solution. Since a majority of subjects maintained reduced VSC 
levels for two-weeks following consumption of K12 lozenges, there is a potential 
role for K12 as a longer-term treatment solution for halitosis.21 As the literature 
supporting the role of S. salivarius K12 in long-term reduction of halitosis is 
relatively minimal, more research will be needed to determine if K12 is a viable 
treatment measure. 
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(5) Oral Candidiasis 
     The overgrowth of Candida albicans, a common yeast species, can result in 
oral pathologies such as oral candidiasis, which is more commonly referred to as 
thrush. Thrush causes severe inflammation as well as the potential for infection, 
especially in populations of individuals who are immunosuppressed.23 In vitro, 
K12 prevents the adherence of C. albicans to a plastic petri dish substratum.23 In 
vivo administration of S. salivarius K12 in a mouse model demonstrates a dose-
dependent reduction in oral candidiasis symptomology. Although administered 
dosages of K12 do not completely eradicate populations of C. albicans, the mice 
tongues have fewer lesions, less fungal growth, and reduced pathogenicity 
(decreased fungal mycelial invasion of tongue epithelium).23 Therefore, the 
overall effect of K12 is the inhibition of C. albicans colonization.  
     The reduction of oral candidiasis by S. salivarius K12 can be attributed not to a 
direct fungicidal effect, but to the bacterium’s ability to directly bind to hyphae of 
C. albicans.23 The probiotic microbe surrounds and attaches to C. albicans during 
fungal germ tube formation and mycelial expansion, which reduces the 
pathogenic yeast’s ability to adhere to substrates.23 K12 preferentially binds to the 
fungal mycelia but not to individual yeast cells themselves. As many of the 
antimicrobial effects of strain K12 are due to its bacteriocin production, the direct 
yeast cell-to-bacterial cell contact is seemingly a unique mode of inhibition. S. 
salivarius K12 thus acts by preventing adhesion of C. albicans to epithelial 
surfaces in the oral cavity, which causes the yeast to be ingested down the 
esophagus to eventually be excreted by the human host.23  
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Safety Assessment of BLIS K12 Oral Probiotics 
     
     Based on its performance in clinical trials and in vitro tests, S. salivarius appears to be 
a highly safe bacterium for human consumption as a probiotic. When an antibiogram test 
for the species was performed using the antibiotic disk sensitivity method, strain K12 
demonstrated sensitivity to many commonly used antibiotics, such as penicillin and 
amoxicillin.1 However, the strain exhibited moderate levels of resistance to gentamicin 
and ofloxacin, with zones of inhibition in the range of 14-18 mm.1 Overall, the bacterium 
lacks resistance to any clinically-significant antibiotics, indicating that even in obscure 
cases of S. salivarius infection, it can be easily combatted by common antibiotic 
treatments. Using two commercially-available microorganism identification tests (the 
API 20 Strep and API 50CH tests), which can help map metabolic profiles of different 
microbes, none of the fermentation or enzymatic reactions that are investigated in these 
commercial tests indicate that strain K12 would have a hazardous effect on humans.1 The 
organism does not produce any hazardous metabolic by-products, such as D-lactate.10 
When this bacterium underwent blood cell lysis testing on human blood agar, sheep 
blood agar, and buffered CNA-P agar, there was no hemolytic activity observed in any of 
these mediums.1 In testing the presence of virulence factors in strain K12 using PCR and 
Southern hybridization, there were no streptococcal virulence determinants or factor 
genes detected in K12.1 At this point in time, there is no genome sequence of S. 
salivarius available. A genome sequence could provide a more in-depth analysis of 
virulence factors in this bacterial species and is one limitation that yields some 
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uncertainty in definitively stating that S. salivarius K12 lacks streptococcal virulence 
factors altogether.  
     In clinical-based safety assessment studies, human subjects consumed lozenges 
containing S. salivarius K12 at regular intervals and reported no adverse symptoms over 
the course of 28 days. There was also no significant change in the levels of S. salivarius 
or facultative anaerobic bacteria in saliva samples of subjects before and after the 
probiotic regimen.1 Additionally, BLIS K12 was tested to identify its potential to 
induce point mutations in microorganisms. A bacterial reverse mutation test was 
performed at varied bacterial concentrations, and the bacterium appeared to lack any 
mutagenicity. In the short-term, even when administered orally to rats at high dosages of 
K12 (5 g/kg), there are no apparent adverse effects caused by the strain. There was no 
sign of cancer, tissue abnormality, or infection acutely after 14 days.10 As the typical dose 
of S. salivarius K12 is 7.5 mg/kg, there is little possibility of toxic effects in humans.10 
Using several health indicators, including gross pathology, biochemical tests, 
hematology, body & organ weight, histopathology, and urinalysis, in sub-acute testing 
(28 days), there similarly was no toxic effect in rats, even at the highest doses.10 In other 
clinical safety assessment studies, 100 healthy adults consumed lozenges with K12 
concentrations of 1x109 CFU and it was determined that after colonization, the bacteria’s 
persistence in the oral cavity was not at levels higher than subjects who naturally possess 
strain K12.10 A final validation of the virtually non-existent toxicity and side-effects is 
the fact that hundreds of thousands of doses have been administered in New Zealand 
(mainly in children) in the past fifteen years and there have been no apparent side-
effects.6 There have been no reports of infections caused by S. salivarius strain K12 or 
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M18, and reports of infection by other S. salivarius strains are generally quite 
uncommon. Between the in vitro and clinical investigations, the data indicates that strain 
K12 has a low pathogenic potential and a minimal chance of causing disease in humans. 
There is essentially no indication that BLIS K12 probiotics have a negative impact on 
humans, and therefore, they appear to be extremely safe for human consumption.    
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Future of S. salivarius Strain K12 & M18 Oral Probiotics 
      
     In the field of probiotic research, there is a present need for more information about 
the relatively novel branch of oral probiotics. As there still is a rather small pool of 
research about S. salivarius strain K12 and M18, future clinical testing will be necessary 
to confirm the roles of these probiotics in terms of practical clinical application. While 
the majority of the oral probiotic research focuses on K12, more research should be 
conducted on M18 and other S. salivarius strains that provide oral health benefits. 
Similarly, much of the current research focuses on the overall effects of K12 and M18 on 
oral health measures, rather than the mechanisms that are the underlying cause of these 
effects; this is one area that particularly needs to be investigated in further detail. Of the 
studies presented in this review, the majority have a small sample size. To improve the 
validity of the data and the accuracy of conclusions that can be drawn from the research, 
more extensive studies should be conducted that are double-blinded, placebo-controlled, 
and have large pools of participants who are randomly assigned to an experimental or 
control group.  
     Despite the limitations of the present studies on the subject, there are several 
socioeconomic implications in the treatment of the described infections, maladies, and 
afflictions through the use of S. salivarius K12 and M18 probiotics. In one study, the 
number of days that recurrent pharyngotonsillitis-prone children who consume 
Bactoblis K12 were on antibiotics (amoxicillin and clavulanic acid) was 30 times lower 
than those who did not take the probiotic lozenges.8 Similarly, the number of days this 
same cohort of children were on antipyretics (acetaminophen and ibuprofen) was 14 
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times lower.8 In addition to an overall reduction in the need for drug treatments, there 
were lifestyle impacts as well. Both children and parents respectively missed 93% less 
school/preschool and work when children followed the K12 regimen compared to those 
who were not treated by the probiotic.8 As antibiotic regimes can be quite costly and 
missed work days can pose a financial burden to families, K12 probiotic treatment could 
be financially advantageous for at least some pools of patients.  
    The oral probiotics discussed in this primary research literature review have the 
potential to be universally utilized as an alternative to antibiotics and/or other treatments 
used to combat and prevent a variety of oral pathologies. As described previously, several 
oral afflictions can be significantly reduced in a clinical setting. Of interest, patients 
presenting with pharyngitis and/or tonsillitis appear to have a particularly promising K12 
treatment outlook based on the data from current literature. Given the present concern 
about the development of antibiotic resistance in bacterial species, to help combat this 
issue, these probiotics could be used as an alternative treatment to antibiotics in milder 
pathogenic infections. Furthermore, since much of the developed world is inextricably 
tied to modern medicine practices, implementing the use of probiotics in clinical practice 
may prove extremely difficult, but not impossible. For example, many dentists in New 
Zealand routinely prescribe K12 and M18 probiotic formulations to prevent dental caries 
and to combat mild gingivitis. In recent years, there has been an increase in probiotic 
usage within the United States and abroad, which, coupled with the excellent clinical 
efficacy demonstrated in a variety of research investigations, bodes well for the future of 
the oral probiotics S. salivarius K12 and M18.    
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